Primary versus radiation-associated craniofacial osteosarcoma
dc.contributor.author | McHugh, Jonathan B. | en_US |
dc.contributor.author | Thomas, Dafydd G. | en_US |
dc.contributor.author | Herman, Joseph M. | en_US |
dc.contributor.author | Ray, Michael E. | en_US |
dc.contributor.author | Baker, Laurence H. | en_US |
dc.contributor.author | Adsay, N. Volkan | en_US |
dc.contributor.author | Rabah, Raja M. | en_US |
dc.contributor.author | Lucas, David R. | en_US |
dc.date.accessioned | 2007-09-18T19:18:12Z | |
dc.date.available | 2007-09-18T19:18:12Z | |
dc.date.issued | 2006-08-01 | en_US |
dc.identifier.citation | McHugh, Jonathan B.; Thomas, Dafydd G.; Herman, Joseph M.; Ray, Michael E.; Baker, Laurence H.; Adsay, N. Volkan; Rabah, Raja; Lucas, David R. (2006). "Primary versus radiation-associated craniofacial osteosarcoma." Cancer 107(3): 554-562. <http://hdl.handle.net/2027.42/55776> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55776 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16795069&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. Craniofacial osteosarcoma differs from long bone osteosarcoma in that patients are older, tumors are often low grade, and prognosis is more favorable. Although most are sporadic, some tumors occur in association with prior radiation therapy. The purpose of the current study was to compare clinicopathologic and prognostic features of primary and radiation-associated osteosarcoma. METHODS. The study group consisted of 15 primary and 6 radiation-associated osteosarcomas. Clinical and follow-up data were obtained in every case. Tissue microarrays were immunohistochemically stained for p53, pRB, Ki-67 (MIB-1), and ezrin. DNA was sequenced for TP53 mutations. RESULTS. All radiation-associated osteosarcomas were high grade and half were fibroblastic. In contrast, 47% of primary craniofacial osteosarcomas were high grade and only 1 was fibroblastic. All radiation-associated osteosarcomas recurred, half the patients died of disease, 2 were alive with unresectable tumors, whereas only 1 was alive without disease. In contrast, 80% of patients with primary tumors were alive without disease, 33% had local recurrences, and 13% died of disease. Radiation-associated tumors overexpressed p53 more often (33% vs. 13%), more often had TP53 mutations (33% vs. 8%), had higher proliferative activity (67% vs. 0% showing >50% MIB-1 staining), and expressed ezrin more frequently (83% vs. 40%) than primary tumors. Compared with a control group of 24 high- and 7 low-grade primary extremity osteosarcomas, radiation-associated tumors marked as the high-grade tumors. CONCLUSIONS. Craniofacial radiation-associated osteosarcomas are high-grade tumors that behave more aggressively than most primary craniofacial osteosarcomas. In addition, they demonstrate higher expression rates of adverse prognostic indicators, further highlighting the distinction. Cancer 2006. © 2006 American Cancer Society. | en_US |
dc.format.extent | 353816 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Primary versus radiation-associated craniofacial osteosarcoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan ; Department of Pharmacology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 763-4095 ; Department of Pathology, University of Michigan, 1500 E. Medical Center Dr., Room 2G332 UH, Ann Arbor MI, 48109-0054 | en_US |
dc.contributor.affiliationother | Department of Pathology, Wayne State University, Detroit, Michigan | en_US |
dc.contributor.affiliationother | Department of Pathology, Wayne State University, Detroit, Michigan | en_US |
dc.identifier.pmid | 16795069 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55776/1/22019_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.22019 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.